Therapeutic drug development is a long and expensive process. Screening for potential toxicity as early as possible may help you select the relevant lead candidates to advance in the drug development process. In this webinar, you’ll learn from hematopoietic expert Dr. Jackie Damen about the importance of hematotoxicity testing in drug development and how hematopoietic colony forming unit (CFU) assays can be applied in toxicity testing to assist in the successful screening of your small molecule compounds and biologics. In her role as Senior Scientific Advisor, Hematopoiesis, as well as her past experience as Director of Contract Assay Services at STEMCELL Technologies, Dr. Damen has conducted hundreds of customized studies involving the CFU assay to provide numerous pharmaceutical and biotechnology clients with solutions to their drug development questions. Email contractassay@stemcell.com for more information.